This assessment hinges on the immunohistochemical appraisal of total (CD3+) and cytotoxic (CD8+) lymphocyte densities in both the centre of the tumour (CT) and the invasive margin (IM) (7). The gene discussed is CD8A; the disease is neoplasm.